In the CELESTIAL trial, cabozantinib exhibited a statistically significant enhancement in overall survival compared to placebo among HCC patients resistant to sorafenib However, the c-MET pathway often engages in cross-talk with other signaling pathways, making c-MET inhibitors such as cabozantinib susceptible to acquired resistance. Here, MET is linked to hepatocellular carcinoma.